Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Feb;105(2):463–469. doi: 10.1111/j.1476-5381.1992.tb14276.x

Reduced α1- and β2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure

Markus Steinfath, Wiebke Danielsen, Heiko von der Leyen, Ulrike Mende, Wilfried Meyer, Joachim Neumann, Monika Nose, Torsten Reich, Wilhelm Schmitz, Hasso Scholz, Jutta Starbatty, Birgitt Stein, Volker Döring, Peter Kalmar, Axel Haverich
PMCID: PMC1908677  PMID: 1348446

Abstract

1 α1-Adrenoceptor (phenylephrine in the presence of propranolol) and β2-adrenoceptor (fenoterol)-mediated positive inotropic effects were investigated in human ventricular preparations isolated from five nonfailing (prospective organ donors) and from eight explanted failing hearts with end-stage idiopathic dilative cardiomyopathy (NYHA IV).

2 For comparison, the nonselective β-adrenoceptor agonist isoprenaline, the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX), the cardiac glycoside dihydroouabain, and calcium were studied.

3 Furthermore, the influence of IBMX on adenosine 3′:5′-cyclic monophosphate (cyclic AMP) PDE activity as well as total β-adrenoceptor density, β1- and β2-adrenoceptor subtype distribution, and α1-adrenoceptor density were compared in nonfailing and failing human heart preparations. The radioligands (—)-[125I]-iodocyanopindolol for β-adrenoceptor binding and [3H]-prazosin for α1-adrenoceptor binding were used.

4 The inotropic responses to calcium and dihydroouabain in failing human hearts were unchanged, whereas the maximal α1- and β2-adrenoceptor-mediated positive inotropic effects were greatly reduced. The inotropic effects of the other cyclic AMP increasing compounds, i.e. isoprenaline and IBMX, were also reduced to about 60% of the effects observed in nonfailing controls. The potency of these compounds was decreased by factors 4–10.

5 The basal PDE activity and the PDE inhibition by IBMX were similar in nonfailing and failing preparations.

6 The total β-adrenoceptor density in nonfailing hearts was about 70 fmol mg-1 protein. In failing hearts the total number of β-adrenoceptors was markedly reduced by about 60%. The β1/β2-adrenoceptor ratio was shifted from about 80/20% in nonfailing to approximately 60/40% in failing hearts which was due to a selective reduction of β1-adrenoceptors. The β2-adrenoceptor population remaining unchanged. α1-Adrenoceptor density was increased from about 4 fmol mg-1 protein in nonfailing to 10 fmol mg-1 protein in failing hearts.

7 Changes in PDE activity and adrenoceptor downregulation cannot completely explain the reduced positive inotropic effects of α1- and β2-adrenoceptor agonists in failing human hearts. This supports the hypothesis that impairment of other processes such as the coupling between receptor and effector system, i.e. the respective G-proteins, are equally important in end-stage heart failure.

Keywords: α1-Adrenoceptor, β2-adrenoceptor, positive inotropic effect, human heart, end-stage heart failure, idiopathic dilated cardiomyopathy

Full text

PDF
463

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggestrup S., Henriksen L., Rygg I. H., Lauridsen P. The cardiovascular and respiratory effects of fenoterol in patients after open-heart surgery. J Cardiovasc Surg (Torino) 1980 Jul-Aug;21(4):409–416. [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  3. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  4. Bristow M. R., Ginsburg R., Strosberg A., Montgomery W., Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul;74(1):212–223. doi: 10.1172/JCI111404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  6. Bristow M. R., Minobe W., Rasmussen R., Hershberger R. E., Hoffman B. B. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 1988 Dec;247(3):1039–1045. [PubMed] [Google Scholar]
  7. Brodde O. E., O'Hara N., Zerkowski H. R., Rohm N. Human cardiac beta-adrenoceptors: both beta 1- and beta 2-adrenoceptors are functionally coupled to the adenylate cyclase in right atrium. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1184–1191. [PubMed] [Google Scholar]
  8. Brodde O. E., Schüler S., Kretsch R., Brinkmann M., Borst H. G., Hetzer R., Reidemeister J. C., Warnecke H., Zerkowski H. R. Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1235–1242. doi: 10.1097/00005344-198611000-00021. [DOI] [PubMed] [Google Scholar]
  9. Brodde O. E., Zerkowski H. R., Borst H. G., Maier W., Michel M. C. Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. Eur Heart J. 1989 Jun;10 (Suppl B):38–44. doi: 10.1093/eurheartj/10.suppl_b.38. [DOI] [PubMed] [Google Scholar]
  10. Brown J. H., Buxton I. L., Brunton L. L. Alpha 1-adrenergic and muscarinic cholinergic stimulation of phosphoinositide hydrolysis in adult rat cardiomyocytes. Circ Res. 1985 Oct;57(4):532–537. doi: 10.1161/01.res.57.4.532. [DOI] [PubMed] [Google Scholar]
  11. Brown L., Näbauer M., Erdmann E. The positive inotropic response to milrinone in isolated human and guinea pig myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1986 Oct;334(2):196–201. doi: 10.1007/BF00505822. [DOI] [PubMed] [Google Scholar]
  12. Brunkhorst D., von der Leyen H., Meyer W., Schmidt-Schumacher C., Scholz H. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium. Arzneimittelforschung. 1988 Sep;38(9):1293–1298. [PubMed] [Google Scholar]
  13. Brückner R., Meyer W., Mügge A., Schmitz W., Scholz H. Alpha-adrenoceptor-mediated positive inotropic effect of phenylephrine in isolated human ventricular myocardium. Eur J Pharmacol. 1984 Apr 6;99(4):345–347. doi: 10.1016/0014-2999(84)90144-4. [DOI] [PubMed] [Google Scholar]
  14. Böhm M., Beuckelmann D., Brown L., Feiler G., Lorenz B., Näbauer M., Kemkes B., Erdmann E. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J. 1988 Aug;9(8):844–852. doi: 10.1093/oxfordjournals.eurheartj.a062577. [DOI] [PubMed] [Google Scholar]
  15. Böhm M., Brückner R., Hackbarth I., Haubitz B., Linhart R., Meyer W., Schmidt B., Schmitz W., Scholz H. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J Pharmacol Exp Ther. 1984 Aug;230(2):483–492. [PubMed] [Google Scholar]
  16. Böhm M., Diet F., Feiler G., Kemkes B., Erdmann E. Alpha-adrenoceptors and alpha-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol. 1988 Sep;12(3):357–364. doi: 10.1097/00005344-198809000-00015. [DOI] [PubMed] [Google Scholar]
  17. Böhm M., Gierschik P., Jakobs K. H., Pieske B., Schnabel P., Ungerer M., Erdmann E. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990 Oct;82(4):1249–1265. doi: 10.1161/01.cir.82.4.1249. [DOI] [PubMed] [Google Scholar]
  18. Böhm M., Pieske B., Schnabel P., Schwinger R., Kemkes B., Klövekorn W. P., Erdmann E. Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved beta 2-adrenoceptor subpopulation. J Cardiovasc Pharmacol. 1989 Oct;14(4):549–559. doi: 10.1097/00005344-198910000-00006. [DOI] [PubMed] [Google Scholar]
  19. Danielsen W., v der Leyen H., Meyer W., Neumann J., Schmitz W., Scholz H., Starbatty J., Stein B., Döring V., Kalmár P. Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol. 1989 Jul;14(1):171–173. doi: 10.1097/00005344-198907000-00026. [DOI] [PubMed] [Google Scholar]
  20. Feldman A. M., Cates A. E., Veazey W. B., Hershberger R. E., Bristow M. R., Baughman K. L., Baumgartner W. A., Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 1988 Jul;82(1):189–197. doi: 10.1172/JCI113569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Feldman M. D., Copelas L., Gwathmey J. K., Phillips P., Warren S. E., Schoen F. J., Grossman W., Morgan J. P. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987 Feb;75(2):331–339. doi: 10.1161/01.cir.75.2.331. [DOI] [PubMed] [Google Scholar]
  22. Ginsburg R., Bristow M. R., Billingham M. E., Stinson E. B., Schroeder J. S., Harrison D. C. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J. 1983 Sep;106(3):535–540. doi: 10.1016/0002-8703(83)90698-1. [DOI] [PubMed] [Google Scholar]
  23. Jakob H., Nawrath H., Rupp J. Adrenoceptor-mediated changes of action potential and force of contraction in human isolated ventricular heart muscle. Br J Pharmacol. 1988 Jun;94(2):584–590. doi: 10.1111/j.1476-5381.1988.tb11564.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jones S. M., Hunt N. A., Del Monte F., Harding S. E. Contraction of cardiac myocytes from noradrenaline-treated rats in response to isoprenaline, forskolin and dibutyryl cAMP. Eur J Pharmacol. 1990 Nov 27;191(2):129–140. doi: 10.1016/0014-2999(90)94140-s. [DOI] [PubMed] [Google Scholar]
  25. Kohl C., Schmitz W., Scholz H., Scholz J., Tóth M., Döring V., Kalmár P. Evidence for alpha 1-adrenoceptor-mediated increase of inositol trisphosphate in the human heart. J Cardiovasc Pharmacol. 1989 Feb;13(2):324–327. doi: 10.1097/00005344-198902000-00023. [DOI] [PubMed] [Google Scholar]
  26. Mügge A., Posselt D., Reimer U., Schmitz W., Scholz H. Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr. 1985 Jan 2;63(1):26–31. [PubMed] [Google Scholar]
  27. Neumann J., Schmitz W., Scholz H., von Meyerinck L., Döring V., Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet. 1988 Oct 22;2(8617):936–937. doi: 10.1016/s0140-6736(88)92601-3. [DOI] [PubMed] [Google Scholar]
  28. Otani H., Otani H., Das D. K. Alpha 1-adrenoceptor-mediated phosphoinositide breakdown and inotropic response in rat left ventricular papillary muscles. Circ Res. 1988 Jan;62(1):8–17. doi: 10.1161/01.res.62.1.8. [DOI] [PubMed] [Google Scholar]
  29. Schmitz W., von der Leyen H., Meyer W., Neumann J., Scholz H. Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol. 1989;14 (Suppl 3):S11–S14. doi: 10.1097/00005344-198914003-00003. [DOI] [PubMed] [Google Scholar]
  30. Scholz J., Schaefer B., Schmitz W., Scholz H., Steinfath M., Lohse M., Schwabe U., Puurunen J. Alpha-1 adrenoceptor-mediated positive inotropic effect and inositol trisphosphate increase in mammalian heart. J Pharmacol Exp Ther. 1988 Apr;245(1):327–335. [PubMed] [Google Scholar]
  31. Schümann H. J., Wagner J., Knorr A., Reidemeister J. C., Sadony V., Schramm G. Demonstration in human atrial preparations of alpha-adrenoceptors mediating positive inotropic effects. Naunyn Schmiedebergs Arch Pharmacol. 1978 May;302(3):333–336. doi: 10.1007/BF00508304. [DOI] [PubMed] [Google Scholar]
  32. Steinfath M., Geertz B., Schmitz W., Scholz H., Haverich A., Breil I., Hanrath P., Reupcke C., Sigmund M., Lo H. B. Distinct down-regulation of cardiac beta 1- and beta 2-adrenoceptors in different human heart diseases. Naunyn Schmiedebergs Arch Pharmacol. 1991 Feb;343(2):217–220. doi: 10.1007/BF00168613. [DOI] [PubMed] [Google Scholar]
  33. Vago T., Bevilacqua M., Norbiato G., Baldi G., Chebat E., Bertora P., Baroldi G., Accinni R. Identification of alpha 1-adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res. 1989 Mar;64(3):474–481. doi: 10.1161/01.res.64.3.474. [DOI] [PubMed] [Google Scholar]
  34. Wilmshurst P. T., Walker J. M., Fry C. H., Mounsey J. P., Twort C. H., Williams B. T., Davies M. J., Webb-Peploe M. M. Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovasc Res. 1984 May;18(5):302–309. doi: 10.1093/cvr/18.5.302. [DOI] [PubMed] [Google Scholar]
  35. Zerkowski H. R., Ikezono K., Rohm N., Reidemeister J. C., Brodde O. E. Human myocardial beta-adrenoceptors: demonstration of both beta 1- and beta 2-adrenoceptors mediating contractile responses to beta-agonists on the isolated right atrium. Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):142–147. doi: 10.1007/BF00511404. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES